Highbridge Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Highbridge Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-95,287	Closed	-$611K	–	1566
2017 Q1	$496K	Buy	+95,287	New	+$382K	0.01%	909
2016 Q3	–	Sell	-69,404	Closed	-$402K	–	1654
2016 Q2	$402K	Buy	+69,404	New	+$442K	0.01%	939
2015 Q2	–	Sell	-23,847	Closed	-$375K	–	1630
2015 Q1	$375K	Buy	+23,847	New	+$369K	0.01%	1051
2014 Q4	–	Sell	-67,194	Closed	-$724K	–	1412
2014 Q3	$724K	Buy	+67,194	New	+$878K	0.01%	761
2013 Q4	–	Sell	-10,270	Closed	-$109K	–	1296
2013 Q3	$109K	Buy	+10,270	New	+$102K	﹤0.01%	1215

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCS

Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's SGMO Position: Q2 2017 in Review

Highbridge Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2017, closing a stake of 95,287 shares — an estimated $611K sold.

Highbridge Capital Management first reported a position in SGMO in Q3 2013 and held it in 5 quarters. The position peaked at $724K in Q3 2014. 143 funds tracked by Wall St. Rank hold SGMO as of Q2 2017.

Highbridge Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 95,287 SANGAMO THERAPEUTICS INC shares in Q2 2017, an estimated $611K.
Highbridge Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 5 quarters.
Highbridge Capital Management's SANGAMO THERAPEUTICS INC position peaked at $724K in Q3 2014.
143 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.